Literature DB >> 28817456

Role of various semiquantitative parameters of 18F-FDG PET/CT studies for interim treatment response evaluation in non-small-cell lung cancer.

Akshima Sharma1, Anant Mohan, Ashu Seith Bhalla, Sreenivas Vishnubhatla, Anil Kumar Pandey, Chandra Sekhar Bal, Rakesh Kumar.   

Abstract

PURPOSE: The aim of this study was to prospectively evaluate the role of various semiquantitative parameters obtained from fluorine-18 fluorodeoxyglucose (F-FDG) PET/CT in interim treatment response assessment in biopsy-proven non-small-cell lung cancer (NSCLC) and to find the best parameter, if any.
MATERIALS AND METHODS: Totally, 32 patients (male/female: 25/7) with biopsy proven NSCLC and a mean age of 54.71±12.65 years were enrolled in the study. Each patient underwent whole-body F-FDG PET/CT scan after injecting 5.18-7.77 MBq/kg of F-FDG intravenously at baseline and after four cycles of chemotherapy. Five parameters - that is, target-to-background ratio (TBR), maximum standardized uptake value (SUVmax), average standardized uptake value (SUVavg), whole-body metabolic tumor volume (MTVwb), and whole-body total lesion glycolysis (TLGwb) - were evaluated for both scans along with their percentage changes ([INCREMENT]). Patients were divided into two response groups as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria: responders and nonresponders. All parameters were compared among the two response groups using appropriate statistical methods; P value of less than 0.05 was considered significant.
RESULTS: All postchemotherapy parameters were found to have a significant role in the prediction of two response groups. Post-TBR had highest area under the receiver operating characteristic curve of 0.83 with a sensitivity and specificity of 75 and 82%, respectively, at a cutoff value of 4. The [INCREMENT]s, [INCREMENT]MTVwb, [INCREMENT]TLGwb, and [INCREMENT]SUVmax were significant with cutoffs of -56, -75, and -32%, respectively. [INCREMENT]MTVwb had the highest area under the receiver operating characteristic curve of 0.83 with sensitivity and specificity of 81.25%. In multivariate analysis, post-TBR and [INCREMENT]MTVwb were found to be the independent variables for prediction of interim treatment response.
CONCLUSION: Our study proves that a multitude of semiquantitative parameters as documented above differ significantly between two response groups in patients with advanced stage NSCLC receiving chemotherapy. Moreover, parameters in combination (ΔMTV and post-TBR) with appropriate cutoffs can predict response groups with acceptable reliability.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28817456     DOI: 10.1097/MNM.0000000000000723

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  7 in total

1.  18F-FDG PET/CT and circulating tumor cells in treatment-naive patients with non-small-cell lung cancer.

Authors:  Fengxian Zhang; Xiaodong Wu; Junjie Zhu; Yan Huang; Xiao Song; Lei Jiang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-02-25       Impact factor: 9.236

2.  SUVmax-Δ makes the difference.

Authors:  Clemens Aigner; Hubertus Hautzel; Till Ploenes
Journal:  Interact Cardiovasc Thorac Surg       Date:  2022-07-09

Review 3.  Progress and future prospective of FDG-PET/CT imaging combined with optimized procedures in lung cancer: toward precision medicine.

Authors:  Haoyue Guo; Kandi Xu; Guangxin Duan; Ling Wen; Yayi He
Journal:  Ann Nucl Med       Date:  2021-11-02       Impact factor: 2.668

4.  Response evaluation after immunotherapy in NSCLC: Early response assessment using FDG PET/CT.

Authors:  Sohyun Park; Youngjoo Lee; Tae-Sung Kim; Seok-Ki Kim; Ji-Youn Han
Journal:  Medicine (Baltimore)       Date:  2020-12-18       Impact factor: 1.817

5.  Feasibility of semiquantitative 18F-fluorodeoxyglucose PET/computed tomography in patients with advanced lung cancer for interim treatment evaluation of combining immunotherapy and chemotherapy.

Authors:  Linping Ke; Leilei Wu; Jinming Yu; Xue Meng
Journal:  Nucl Med Commun       Date:  2021-09-01       Impact factor: 1.698

6.  Prognostic Significance of SUVmax Combined With Lactate Dehydrogenase in Advanced Lung Cancer Patients Treated With Immune Checkpoint Inhibitor Plus Chemotherapy: A Retrospective Study.

Authors:  Linping Ke; Lu Wang; Jinming Yu; Xue Meng
Journal:  Front Oncol       Date:  2021-05-18       Impact factor: 6.244

7.  Incorporation of circulating tumor cells and whole-body metabolic tumor volume of 18F-FDG PET/CT improves prediction of outcome in IIIB stage small-cell lung cancer.

Authors:  Lei Fu; Ying Zhu; Wang Jing; Dong Guo; Li Kong; Jinming Yu
Journal:  Chin J Cancer Res       Date:  2018-12       Impact factor: 5.087

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.